Intelligence · Patents
Patents expiring in 2041
Annual patent cliff calendar for 2041 — US pharmaceutical patents by expiration date.
- Patents
- 2,000
Quick answer
2,000 indexed pharmaceutical patents have expiration dates in 2041. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11084850
Recombinant prefusion RSV F proteins and uses thereof
granted -
US 11084865
VEGF antagonist formulations suitable for intravitreal administration
granted -
US 11083696
Dispersion anaesthetic device
granted -
US 11083801
Factor VIII mutation repair and tolerance induction
granted -
US 11083635
Tampon delivery system for a pharmaceutical, holistic or medicinal component
granted -
US 11084798
2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
granted -
US 11084842
Glucopyranosyl derivative and use thereof
granted -
US 11083708
Pharmacological restoration of epithelial or endothelial barrier integrity by agents blocking EPAC/RAP1 signaling
granted -
US 11083720
Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases
granted -
US 11083736
Compositions comprising triterpenoids
granted -
US 11083752
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted -
US 11091525
Method of refolding an interleukin-2 (IL-2) protein
granted -
US 11091467
Modulators of THR-β and methods of use thereof
granted -
US 11090224
Adaptor for a dispensing container in a planetary mixer
granted -
US 11090286
Methods of treating and preventing breast cancer with S-equol
granted -
US 11090290
Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy
granted -
US 11090272
Lurasidone solid dispersion and preparation method thereof
granted -
US 11090325
Compositions for treating ebola virus infection
granted -
US 11090326
Fixed-dose pharmaceutical composition comprising rifabutin, clarithromycin, and clofazimine
granted -
US 11090310
Methods and compositions for treating hypertriglyceridemia
granted -
US 11090313
Methods for inhibiting muscle atrophy
granted -
US 11090349
Plant extract obtained from Morus plant leaves, compositions containing same, method of extraction and uses thereof
granted -
US 11090361
Activin receptor type IIa variants and methods of use thereof
granted -
US 11090396
Compounds and methods for the detection of TRPV-6 cancers and drug delivery
granted -
US 11091441
Solid state crystalline forms of a selective potassium channel modulator
granted -
US 11091473
Compounds for pain treatment, compositions comprising same, and methods of using same
granted -
US 11091464
Pyridazinone compounds and uses thereof
granted -
US 11091795
Compositions and methods for diagnosing and treating arrhythmias
granted -
US 11091761
Organic compositions to treat HSF1-related diseases
granted -
US 11091561
HER-2 binding antibodies
granted -
US 11091555
Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapy
granted -
US 11091532
T cell which co-expresses a CD19 chimeric antigen receptor and a CD22 chimeric antigen receptor
granted -
US 11091534
Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
granted -
US 11091529
Peptides having reduced toxicity that stimulate cholesterol efflux
granted -
US 11091519
Purification of virus like particles
granted -
US 11091518
Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
granted -
US 11091516
Synthetic binder of breast cancer stem cells
granted -
US 11091509
HPPK inhibitors useful as antibacterial agents
granted -
US 11091501
Heterocyclic compounds as RSV inhibitors
granted -
US 11091495
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted -
US 11090293
Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
granted -
US 11090269
Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
granted -
US 11090285
Treatment of circadian rhythm disorders
granted -
US 11090332
Antigen specific mRNA cellular cancer vaccines
granted -
US 11090344
Adenovirus and immunomodulator combination therapy
granted -
US 11091472
PI-kinase inhibitors with anti-infective activity
granted -
US 11090311
Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer
granted -
US 11090308
Methods of treating liver disorders or lipid disorders with a THR-beta agonist
granted
Frequently asked questions
How many pharma patents expire in 2041?
2,000 published patents in our USPTO index have expiration dates falling in calendar year 2041.